The earnings call reflects a strong financial performance with significant revenue growth driven by Jornay PM and the pain portfolio. Despite challenges such as increased operating expenses and a decline in GAAP net income, the company's outlook remains positive with raised financial guidance and strategic investments paving the way for future growth.

Company Guidance

During the Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call, the company provided updated financial guidance and highlighted key performance metrics. Collegium reported a 29% year-over-year increase in quarterly revenue, reaching $188 million, with Jornay PM contributing $32.6 million, marking a 23% rise in prescriptions. Their pain portfolio also saw a 7% revenue growth, totaling $155.4 million. The company raised its 2025 financial guidance, now anticipating a 19% year-over-year revenue growth, with expectations for Jornay's revenue to reach between $140 million and $145 million, a 42% increase from 2024. Adjusted EBITDA is projected to grow by 12% year-over-year. The firm continues to enhance shareholder value through a $25 million share repurchase and a newly authorized $150 million program, while maintaining a strong cash position of $222 million and reducing debt significantly.

Record Quarterly Revenue and Growth

Collegium Pharmaceuticals reported record quarterly revenue, growing 29% year-over-year, with adjusted EBITDA up 9% year-over-year.

Strong Performance of Jornay PM

Jornay PM prescriptions grew 23% year-over-year, generating record quarterly revenues of $32.6 million. Jornay's market share of the long-acting branded methylphenidate market grew to 23%, up 7.6 percentage points year-over-year.

Pain Portfolio Growth

The pain portfolio generated record revenue of $155.4 million, up 7% year-over-year, with all three core pain medicines showing year-over-year revenue growth.

Increased Financial Guidance for 2025

The company raised its 2025 financial guidance, expecting total revenue growth of approximately 19% year-over-year and adjusted EBITDA growth of approximately 12% year-over-year.

Significant Cash Flow Generation

Collegium generated $72.4 million in cash from operations, growing the cash position to $222 million while paying down $16.1 million of debt and repurchasing $25 million in shares.

Collegium Pharmaceutical (COLL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

COLL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	1.88 / -	1.61	―	―	―
Aug 07, 2025	2025 (Q2)	1.62 / 1.68	1.62	3.70% (+0.06)
May 08, 2025	2025 (Q1)	1.43 / 1.49	1.45	2.76% (+0.04)
Feb 27, 2025	2024 (Q4)	1.54 / 1.77	1.58	12.03% (+0.19)
Nov 07, 2024	2024 (Q3)	1.59 / 1.61	1.34	20.15% (+0.27)
Aug 08, 2024	2024 (Q2)	1.49 / 1.62	1.26	28.57% (+0.36)
May 09, 2024	2024 (Q1)	1.47 / 1.45	1.32	9.85% (+0.13)
Feb 22, 2024	2023 (Q4)	1.38 / 1.58	1.09	44.95% (+0.49)
Nov 07, 2023	2023 (Q3)	1.22 / 1.34	1.1	21.82% (+0.24)
Aug 03, 2023	2023 (Q2)	1.22 / 1.26	1.183	6.51% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

COLL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$29.75	$32.94	+10.72%
May 08, 2025	$27.27	$28.89	+5.94%
Feb 27, 2025	$28.42	$29.05	+2.22%
Nov 07, 2024	$34.71	$32.16	-7.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Collegium Pharmaceutical (COLL) report earnings?

Collegium Pharmaceutical (COLL) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Collegium Pharmaceutical (COLL) earnings time?

Collegium Pharmaceutical (COLL) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is COLL EPS forecast?

COLL EPS forecast for the fiscal quarter 2025 (Q3) is 1.88.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing